Extension Study of MYL-1701P-3001 for Safety and Efficacy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-23

Study Completion Date

2022-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

NCT03610646

Diabetic Macular Edema

COMPLETED PHASE3

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)

NCT02818998

Macular Edema

COMPLETED PHASE3

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America

NCT03470103

Macular Degeneration

COMPLETED

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

NCT05324592

Diabetic Macular Edema

COMPLETED PHASE1

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

NCT06398080

Neovascular Age-related Macular Degeneration (nAMD) Wet Age-related Macular Degeneration (AMD) Diabetic Macular Edema (DME) +1 more

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetic retinopathy is an important cause of blindness worldwide. The International Diabetes Federation estimates that 285 million people worldwide have diabetes mellitus and approximately 7% of these individuals are affected by diabetic macular edema.

EYLEA® (aflibercept) injection, an anti-Vascular Endothelial Growth Factor (VEGF) agent, has been approved by the FDA and EMA for the treatment of Diabetic Macular Edema (DME).

Mylan Inc. and Momenta Pharmaceuticals, Inc. are developing MYL-1701P, a proposed biosimilar to Eylea.

MYL-1701P-3001 study was designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of MYL-1701P in the treatment of subjects with Diabetic Macular Edema (DME). Eligible subjects from MYL-1701P-3001 study will be enrolled in the AFIL-IJZ-3002 study. All enrolled subjects will receive three doses of MYL-1701P every eight weeks. Subjects will attend the clinic visits for safety and efficacy assessments including BCVA, SD-OCT, complete ophthalmological examinations during the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single, test arm

MYL-1701P- Subjects will receive 3 doses each of 2 mg at 8 weeks interval

Group Type EXPERIMENTAL

MYL-1701P, a proposed biosimilar to Eylea

Intervention Type BIOLOGICAL

Open label and single arm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MYL-1701P, a proposed biosimilar to Eylea

Open label and single arm

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject participated in the MYL-1701P-3001 study
2. Subject requires treatment with intravitreal anti-VEGF therapy
3. Subject is able to understand and voluntarily provide written informed consent to participate in the study.
4. If female of childbearing potential, the subject must have negative pregnancy tests and should not be nursing or planning a pregnancy.
5. Subject is willing to comply with the study duration, study visits and study related procedures.
6. If female, subject must be:

* Surgically sterilized via hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; or
* Of childbearing potential and practicing an acceptable form of birth control
* Of non-childbearing potential
7. If male, subject must be surgically or biologically sterile. If not sterile, the subject must agree to use an acceptable form of birth control

Exclusion Criteria

1. Subjects with known hypersensitivity to aflibercept or any of the excipients
2. Subjects will be excluded if any of the following conditions are met in the study eye:

* Subjects with active ocular inflammation.
* Subjects with uncontrolled glaucoma
* Surgery for glaucoma in the past or likely to be needed in the future.
3. Subjects with active or suspected ocular or periocular infection including but not limited to infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye.
4. Subjects who plan to participate in another clinical study while enrolled in this study.
5. Subjects receiving treatment for a serious systemic infection.
6. Subjects with uncontrolled hypertension defined as systolic blood pressure \> 160 mm Hg or diastolic blood pressure \> 95 mm Hg.
7. Subjects with a history of cerebrovascular accident or myocardial infarction within 6 months of enrollment.
8. Subjects with renal failure requiring dialysis or renal transplant.
9. Subjects with a history or presence of any clinically significant condition, that in the opinion of the Investigator would jeopardize the safety of the subject or the validity of the study results.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No